After 18 years of bagels, Silverbow Bakery to close Oct. 4

first_imgBusiness | Economy | Food | Juneau | KRNNAfter 18 years of bagels, Silverbow Bakery to close Oct. 4September 14, 2015 by Lisa Phu Share:Jill Ramiel opened the Silverbow Bakery in 1997. It’s closing Oct. 4. (Photo by Lisa Phu/KTOO)The Silverbow Bakery in downtown Juneau is closing. For 18 years, the eatery has been a popular gathering spot for locals and visitors. It’s known for its cookies, soups and sandwiches and, of course, its bagels.Audio Player Up/Down Arrow keys to increase or decrease volume.Nicky Love, 30, is a longtime Silverbow Bakery customer. She’s been coming here for most of her life.Nicky Love has been a Silverbow customer since she was a kid. Now, she brings her own kids to the restaurant. (Photo by Lisa Phu/KTOO)“Silverbow is definitely something I think of when I’ve been away and think about home,” Love said.You can find Love at Silverbow two to three times a week. On this day, she’s seated at a corner table, typing on a tablet. Several others in the dining area are doing the same.“I’ve been a fan of the breakfast bagel with sausage and egg and cheese and it’s huge and messy and filling. I think I’ve had that almost every time I come here,” Love said.Love has memories of getting lunch here as a high schooler. As an adult, “I can come here with my kids now and they have somewhere fun to play. It’s kid-friendly environment.”Love considers Silverbow an integral part of Juneau’s fabric. She’s in shock that it’s closing.“It’s taken a minute to sink in. I’m going to be really sad to see it go,” Love said.Silverbow owner and operator Jill Ramiel says she’s heard similar sentiments from other customers.“It has been fantastic how many people have come out and been emotionally distraught about it. And I was like, ‘Wow, I had no idea that bagels had such an impact on people.’ Or people say, ‘My kids grew up here,’ and then I say, ‘Oh my gosh, it’s been way too long. I’ve been doing this too long,’” Ramiel said.During the bagel shop’s early years, owner and operator Jill Ramiel worked the front counter every day and baked twice a week. (Photo by Lisa Phu/KTOO)Ramiel is originally from New York and went to school in Seattle to study architecture. She worked in Juneau the summer of 1996. She says Juneau was missing a place to grab a quick lunch.“And a bagel place was what I grew up with. You eat bagels every day after school. It seemed like the most normal thing to me. I didn’t realize it wasn’t the most normal thing for everyone in Juneau at that time,” Ramiel said.Ramiel bought a historic building on Second Street and renovated it. The bakery opened in June 1997.Over the years, the Silverbow has hosted art exhibits, Alaska Folk Fest singers, movie showings and World Cup events. Ramiel and her husband Ken Alper also operate the attached Silverbow Inn.“We still own this building and we still live above it and we’re still raising three kids in this community and we still run an 11-room hotel, so we have no plans to leave,” Ramiel said.Ramiel is putting her energy into another business venture, Juneau Legacy Properties. She and her business partners want to transform a historic Juneau building, like she did.“When I look back, that’s really what I liked the most was taking something that maybe is dilapidated or maybe it’s underutilized and making it fresher and newer and having new energy put into it,” Ramiel said. “And so we’ve been looking for a building to buy and I would love to add more hotel rooms, or apartments and residences. There’s a lot of options.”Silverbow Bakery is most known for its bagels. It’s last day of operation is Oct. 4. On that day, Ramiel said everything will be priced like it was in 1997. (Photo by Lisa Phu/KTOO)Ramiel is going to miss being a part of people’s everyday lives. But she won’t miss the long, endless hours.“Because our operation functions 24 hours a day, my bakers work all night long and things go wrong all the time. So I’m looking forward to one solid night of sleep,” Ramiel said.While the Silverbow Bakery is closing, what it’s most known for isn’t going away. The business taking over promises to carry on the bagel tradition.Share this story:last_img read more

10 lessons for building a game-changing biotech company

first_img Related: [email protected] Camille Samuels Racquel Bracken 8. Scrappy is best. Using other people’s money is good too. The capital intensity of the biotech industry is one of the major reasons that its returns for founders and investors can sometimes be modest. Ideally, you will knock down major risks with small amounts of capital and then press the accelerator on growth once you know your path. Unity, which Venrock seeded, is an example of a company that executed on this strategy. Alternatively, if you must grow infrastructure early, supplement expensive equity capital with creative sources of “non-dilutive” capital like other people’s money (OPM). Possible sources of OPM include strategics, cash flow from adjacent businesses, government monies, and debt.9. Be a master storyteller. The very best biotech founders and CEOs not only execute carefully but also weave compelling stories. The best employees, investors, and partners join a mission, not an asset. Masterful story telling helps you avoid “drip-feed” financing and B-player teams.10. Work backward from your target company profile and your target product profile. Is your vision to create a single-product company or one with a rich pipeline of drugs? Do you want to hold on for the long run or sell early? Your answer to what kind of company you want to build has dozens of strategic implications. When you finally have a product in the clinic, ask what target product profile will actually compel a clinician to prescribe? Far too often we see companies focus on what is merely approvable (versus clinically useful) or what gets them through the next study — disastrous short-term decisions that fail to build long term value.We believe that we are in a golden age of biotech. Making great foundational choices and partnering with a hardworking, experienced investor can help ensure that your company gets that gold.Racquel Bracken and Camille Samuels invest in private health care companies at Venrock, a venture capital firm devoted to helping entrepreneurs build important and enduring companies. (Samuels holds personal shares in Unity, a company mentioned in this article.) 4. Goldilocks had it right. Get your funding “just right.” Raise too little capital and you won’t make it to your milestones; raise too much and you will dilute yourself. Be thoughtful and realistic about designing your value-creating milestones and capital needs. Milestones are a commitment to your team and your investors — an implicit agreement about what will be achieved given a certain amount of time and money.5. Zig when others zag and, when you do, swing for the fences. Venrock is anti-herd and pro-big ideas. Like you, we seek drugs and technologies that change the practice of medicine. Being first to a category can be revolutionary. So can being the best: a great strategy can be to dive deeply into a category just as others are getting discouraged by it. Learn from Version 1.0 and be best with Version 2.0 (or 3.0).6. Know your customer. On the long and risky road to getting a product on the market, biotech CEOs and many of their investors forget who their true customers are: patients, physicians, and payers. Investors are not your customer, so don’t whipsaw your company in response to every investor idea or pushback. If your north star is solving unmet needs for patients, investors will ultimately line up.7. Don’t bother sharing a cupcake. There are lots of cupcake biotech businesses — delicious opportunities in smaller markets — but not everyone wants to share something small. These opportunities can yield wonderful returns for founders, but shouldn’t take on the dilution of venture capital. If your market size is less than $500 million or your business needs only $10 million to break even, angels are a better funding source. 2. Platforms are good but killer applications are paramount. Foundational technology platforms (like genomics, antibodies, and CRISPR) have led to some major biotech successes. Yet their ultimate valuation typically comes not just from the founding technology, but also from the drugs uniquely enabled by that technology. Selection of the platform’s killer apps — the clinical indications to which the platform will be applied — will make or break your company. We have seen many companies betting the farm on a highly risky first app, and when that first drug fails, the entire technology platform loses its day in the sun. Other companies pick apps where their technology doesn’t have a competitive advantage, simply because that clinical application is “hot” with investors and strategics. Good venture capitalists can be extremely helpful when picking optimal apps. 3. Fail fast. A quick, capital-efficient “no” is better than a long maybe. Identify the biggest risks and find a way to address them early. You will be tempted to delay a failure, but do so at your company’s peril.advertisement APStock About the Authors Reprints Biotech financing, both public and private, has been choppy since September 2015. Yet some companies haven’t missed a beat. These “haves” continue to command high valuations and didn’t need to moderate their lofty aspirations. Not so for the “have nots.”We have the privilege of working at Venrock, a firm that has funded, and continues to fund, highly successful companies such as Gilead, Juno, Illumina, and Intarcia. We’ve also seen our fair share of have-nots. Here are 10 of the key lessons we’ve learned about how to build game-changers in biotech.1. Be uncompromisingly choosy. The road to success often takes 10 years or more and is sure to be bumpy. Be relentlessly discerning when it comes to choosing your investors and team. You are likely to see and speak with these people more than your closest friends for the next significant chunk of your waking hours. Pick your team and your investors based on trust, their embrace of truth-seeking, and perseverance. Beware of fair-weather investors, and those who are likable but ineffective.advertisementcenter_img By Racquel Bracken and Camille Samuels Dec. 1, 2016 Reprints @CamiSamuelsVC First Opinion10 lessons for building a game-changing biotech company Related: @rnbracken 5 top blunders life science startups make on the road to clinical trials Tags biotechnologydrug developmentfinancing Investing in a startup? Follow the data, not the herd [email protected] last_img read more

Employers shoulder plenty of drug costs, but haven’t lobbied much to lower them — until now

first_imgPolitics Employers shoulder plenty of drug costs, but haven’t lobbied much to lower them — until now Log In | Learn More Adobe WASHINGTON — Companies like Pepsi, Walmart, and Jack in the Box foot the bill for more than 150 million Americans’ prescription drug needs. But in Washington, where both Democrats and Republicans have launched into major campaigns to lower prescription drug prices, the bulk of the conversation about how to lower prescription drug prices has focused on changes to Medicare.  Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED About the Author Reprints GET STARTED What’s included? Nicholas Florkocenter_img Tags advocacyCongressdrug pricingSTAT+ Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. By Nicholas Florko Feb. 3, 2020 Reprints [email protected] What is it? Washington Correspondent Nicholas Florko reports on the the intersection of politics and health policy. He is the author the newsletter “D.C. Diagnosis.” @NicholasFlorko STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.last_img read more

Doctors anticipate patient requests for experimental remdesivir before all the evidence comes in

first_img @cooney_liz By Elizabeth Cooney April 30, 2020 Reprints An ICU staff member cares for a Covid-19 patient at St. Joseph’s Hospital in Yonkers, N.Y. John Minchillo/AP General Assignment Reporter Liz focuses on cancer, biomedical engineering, and how patients feel the effects of Covid-19. Still, doctors on the frontlines are sounding notes of caution and asking questions while they lead trials themselves.“It’s not a magic bullet. It’s not a drug that’s a quick answer to the epidemic, but it’s a step in the right direction,” said Otto Yang, a professor of medicine at the David Geffen School of Medicine at UCLA who is leading an NIAID remdesivir trial at the UCLA study site. “These were seriously ill patients. One question I have is will it work better in patients that are not so ill? Will it work as prevention? These are really key questions.” advertisement [email protected] Newsletters Sign up for Daily Recap A roundup of STAT’s top stories of the day. Constance Benson, professor of medicine at the University of California, San Diego, School of Medicine and co-leader of an NIAID clinical trial there, is expecting to hear from patients. Privacy Policy “After getting burned a little bit with some more data coming out suggesting that [hydroxychloroquine] is not very useful, I think people are slightly less inclined to jump at the starting gun,” he said. “There’s still interest from patients, don’t get me wrong. But there’s not that kind of rabid desire that there was before. I think people recognize the scientific process has a role to play here.”Robert Finberg, chief of medicine at UMass Memorial Medical Center in Worcester, Mass., encourages patients to join trials of remdesivir. “That’s the way we find out whether things work,” he said. “I think we’ve been very rewarded by the outcomes. Now, obviously, some people are going to get better on their own. And that’s great, too.”It’s families posing these questions, said Sarge, at Beth Israel Deaconess, when patients themselves are so sick they need ventilators to breathe. The families’ anxiety is magnified when hospital rules mean they can’t visit their loved ones, he suspects. As they grasp for answers, something like remdesivir may look promising.One family told Sarge they’re getting calls from friends and family members urging them to ask about possible treatments they learned from the news. “They need to do something,” he said. “Sometimes that ‘something’ ends up being repeating back the news around various experimental therapies that they then request.”STAT contributor Usha Lee McFarling and STAT national technology correspondent Casey Ross contributed reporting. Elizabeth Cooney Before Wednesday’s hopeful news about the experimental antiviral remdesivir broke, doctors treating patients hospitalized for Covid-19 were already hearing from a few families desperate to get the drug for their loved ones. Now they expect to hear more pleas in the days to come, even though the data are preliminary, results are not available for clinicians to evaluate, and the drug is not yet approved for emergency use.“Obviously, anything positive with regard to treatment is encouraging,” said Todd Sarge, medical director of the surgical intensive care unit at Beth Israel Deaconess Medical Center in Boston. “What concerns me has been these things get very much hyped up in the news, and [patients’ families] will definitely be requesting it more often. And that can be a difficult conversation between families and our clinicians because for one, it’s still experimental, and two, it’s not widely available yet.”Wednesday’s news came from a study led by the National Institute of Allergy and Infectious Diseases. In the double-blind, randomized controlled trial of 800 people, hospitalized Covid-19 patients who received the drug recovered in 11 days versus 15 days for patients who got a placebo. That design is considered the gold standard because no one knows who is or isn’t getting the drug, minimizing the chance of bias in judging outcomes.advertisement Tags BostonCoronavirusdrug developmenthospitalspatientspharmaceuticals About the Author Reprints Leave this field empty if you’re human: “It’s been picked up by the news media and it has quickly crawled across our desk with people asking questions,” she said. “I’m sure every physician who encounters patients will be asked about this, who can get it and how can they get it? We don’t really have answers for that yet.”At Brigham and Women’s Hospital in Boston, patients aren’t clamoring for remdesivir, said Francisco Marty, an infectious disease physician who is leading a trial there. He points to language as a barrier slowing the spread of news accounts about the antiviral. “What has been particularly shocking to me, because I’ve been doing trials for the last 18 years, is how mostly minorities have been affected,” he said. The hospital’s patient population for research trials is typically 80% Caucasian and 20% minority, but that ratio has flipped. “I speak Spanish as my mother tongue. I’ve never done so many consents in Spanish before.”Dan Culver, a pulmonologist and critical care physician at the Cleveland Clinic and director of its therapeutics assessment committee, compared Wednesday’s news to more prolonged interest in antimalaria drugs. “Because of all the wide variety of different information patients are getting, it’s become a bit of a cacophony of ideas,” he said, adding that he’s not been getting as many inquiries about remdesivir as hydroxychloroquine. “That got more touted on the political end of things.” Related: An updated guide to the coronavirus drugs and vaccines in development Please enter a valid email address. HealthDoctors anticipate patient requests for experimental remdesivir before all the evidence comes in last_img read more

EU approves minimum four-year jail term for market manipulation

first_img European policymakers have approved a new effort to combat market manipulation by introducing criminal sanctions for these sorts of violations. The European Commission welcomed a vote Tuesday by the European Parliament approving the commission’s proposal for a directive on criminal sanctions for market abuse. The directive will require countries to make market manipulation, including the manipulation of benchmarks, a criminal offence, punishable with effective sanctions everywhere in Europe. They will have two years to implement the directive in national law. Facebook LinkedIn Twitter SEC alleges trader used tweets to pump and dump stock Pump and dump ends in ban, over $1 million in penalties Share this article and your comments with peers on social media Keywords Market manipulation,  Europe center_img James Langton Related news Mouth mechanic turned market manipulator Under the directive, there will be common EU definitions of market abuse offences such as insider dealing, unlawful disclosure of information and market manipulation; and, there will be a common set of criminal sanctions including fines and imprisonment of four years for insider dealing/market manipulation and two years for unlawful disclosure of inside information. The commission says that the verdict demonstrates Europe’s commitment to combat insider dealing and market manipulation in its financial markets. “Today the European Union is sending a clear signal: there must be zero tolerance for manipulators in our financial markets. The EU’s new market abuse framework will ensure that those who commit market abuse will face huge fines or jail across Europe,” said vice president, Viviane Reding, the EU’s justice commissioner and Michel Barnier, internal market and services commissioner.last_img read more

Hotline Providing Public with Critical Information

first_imgRelatedHotline Providing Public with Critical Information RelatedHotline Providing Public with Critical Information Advertisements Hotline Providing Public with Critical Information UncategorizedNovember 2, 2008center_img RelatedHotline Providing Public with Critical Information FacebookTwitterWhatsAppEmail Minister of Energy, Clive Mullings has revealed that the E10 hotline is in “full swing” and that a number of Jamaicans have been calling to get information on the soon to be introduced bio-fuel.“The hotline is up and running. People are calling from as early as 6:45 in the morning, making enquiries and I hope more persons will call to get information,” he said in an interview with JIS News. The E10 hotline number is 1888-429-5310 and is open between 8:30 a.m. to 4:30 p.m. from Mondays to Fridays.Additionally, to ensure that the public is cognisant of and understands the different issues associated with the E10 fuel, the E10 team, which comprises representatives from the Ministry of Energy, the Petroleum Corporation of Jamaica (PCJ), and Petrojam, has produced and is distributing an E10 questions and answers brochure.When asked “What if I use E10 and go out of town where none is available, can I top up with regular gasoline?” the brochure responds “Yes, you can top up with regular gasoline as Methyl Tertiary Butyl Ether (MTBE) and E10 gasoline can be mixed”.In terms of compatibility the main concern is the effect, if any that the E10 fuel will have on older cars.The brochure states that: “In general, 1980 and later model years should not experience problems with E10. Fuel systems in the 1975 to 1980 model years were upgraded, but not to the same extent as later models. Pre-1975 models may have fuel components that are sensitive to E10 such as fuel line hoses, gaskets, and seals. If not already changed, these components may require replacement although the useful life of such components would have likely been exceeded already”.However, to ensure absolute certainty regarding compatibility, Minister Mullings is still encouraging motorists to check with their manufacturers and dealers before using E10.Other questions asked refer to the benefits to be derived from the E10 fuel and assurances regarding its quality.With respect to the benefits, the brochure lists less ground water contamination than MTBE gasoline (regular), reduction in tailpipe emissions, and states that sugar cane derived ethanol is a renewable fuel and that greater quantities of ethanol reduces the demand for imported fossil fuels, thereby saving the country foreign exchange.Furthermore, it states that ethanol burns cooler and cleaner in engines therefore reducing the need for fuel injector cleaners. Dirty filters can reduce efficiency by approximately three per cent, it said, therefore, the scouring properties of ethanol cleans filters as an added benefit. In addition, there is the potential for job creation especially in the sugar industry.On the critical issue of quality, the question is asked: “How do I know that I am not getting “bad” gas? The E10 team highlights a number of safeguards that are in place to protect consumers. These include: the Petroleum Quality Act, which sets specifications for all gasoline products that are sold in Jamaica; random sample and testing of gasoline across the island by the Bureau of Standards, and the Ministry of Energy, to verify quality; quality analysis carried out by the Petrojam refinery on every batch of gasoline and ethanol used to produce E10 at its internationally certified lab; and calibration of Petrojam blendskids to ensure accuracy.Other safeguards include: strict stewardship practices carried out by the haulage contractors and service station operators, to ensure quality, including, regularly dipping the E10 with water finding paste to detect any water abnormality, visual inspection of the product, and mixing cylinder test to determine if there is water contamination and phase separation. Service stations will use special (10 micron) filters when dispensing E10, thereby protecting the customer from receiving water or debris in the gasoline.E10 or 10 per cent ethanol in 90 per cent 87 octane, will be introduced on a phased basis starting tomorrow (November 1), with a launch at the Petcom, Portmore service station. Jamaica will join a number of developed countries such as the United States of America, Canada, Sweden, and Brazil that uses ethanol blended fuel.Ethanol is the highest rated octane fuel on the market as it extends gasoline, does not leave gummy deposits, and keeps the vehicle’s fuel system clean for optimal performance. Ethanol is now accepted worldwide as the most compatible, economically and environmentally feasible replacement for MTBE.last_img read more

CU-Boulder Confirms Second Case of A(H1N1) in Student Living Off Campus

first_imgThe University of Colorado today confirmed through the Boulder County Health department a second case of A(H1N1) virus in a CU-Boulder student.The case involves a student who lives off campus. The student is self-isolating and is completing end-of-the-semester work from home.CU medical officials say there is little public health risk from the case.”As we have said previously, a few cases of the virus on campus does not constitute a health threat to the general population,” said Dr. Pamela Talley, lead physician for the medical clinic at CU-Boulder’s Wardenburg Health Center. “The two students are recovering and self-isolating, and we have taken precautions with the rest of our students on campus.”Final examinations will end on schedule on Thursday, and commencement is scheduled for Friday morning at 8:30 a.m. in Folsom Field. Hand gel and extra tissues will be available for attendees at commencement.”There is no increased health risk for guests who might attend commencement or who are picking up their students in the residence halls over a normal flu season,” said Talley. “We do advise those at risk for complications from any flu – pregnant women, people with immuno-suppression (cancer patients, diabetics) or parents who may have small children – to take precautions in large public gatherings, whether on campus or elsewhere.”Health officials also advise visitors, faculty, staff, students and CU visitors to read and practice the basic health measures outlined by the CDC at .”This flu, again, is behaving like a seasonal flu virus,” said Talley. “We’re not seeing the severity that we’ve seen even with past seasonal viruses, so the medical risk to the general community is still not great. But people need to be vigilant regarding standard preventative measures about hand-washing, covering their faces and mouths when they sneeze or cough, and not venturing out into public places if they have a fever and a cough.” Share Share via TwitterShare via FacebookShare via LinkedInShare via E-mail Published: May 6, 2009 last_img read more

Australian PGA ahead of Aussie Open in ’19 to accommodate Presidents Cup

first_imgGOLD COAST, Australia – Next year’s Australian PGA Championship will precede the Australian Open so it can accommodate the Presidents Cup in mid-December at Royal Melbourne. Officials said the 2019 Australian PGA will be played at Royal Pines on the Gold Coast from Nov. 28 to Dec. 1, a week ahead of the Australian Open (Dec. 8-11 at The Australian in Sydney) and the Presidents Cup (Dec. 12-15). This year, the Open, won by Mexico’s Abraham Ancer, preceded the PGA by two weeks, with the World Cup of Golf at Metropolitan in Melbourne in between. The World Cup team event was won by Belgians Thomas Pieters and Thomas Detry, with Cameron Smith and Marc Leishman, representing Australia, tied for second. This year’s Australian PGA begins Thursday with defending champion Smith and Leishman among the entries. Also entered are Geoff Ogilvy, who was named as a vice captain on Sunday by captain Ernie Els for the Presidents Cup, England’s Andrew (Beef) Johnston and American Harold Varner III, who has won, finished second in a playoff and finished sixth in three Australian PGAs at Royal Pines.last_img read more

OECD 50th Anniversary Video Competition

first_img January 31, 2011 Published by Site Default Pocket YOUNG LEADERS – 2021 EDITION World Forum for Democracy 2020: Call for Initiatives Share 0 LinkedIn 0 Leave a Reply Cancel ReplyYou must be logged in to post a comment. ← Stereotypical Stereotype Breaker Deadline: 1 March 2011 (midnight, Paris time)Open to: young people (18-25 years)Award: the winner will be invited to the OECD Forum in May 2011, with travel cost, hotel accommodation and daily allowance paidTo commemorate its 50th anniversary, OECD launched a video competition to young people all around the world.EligibilityYoung people (18-25 years) in every country worldwide.ApplicationSubmit your video by responding to the OECD competition video on YouTube (the video above), do not forget to complete and submit the online registration form by the deadline.Your video must complete the title: ” Progress is…”Video Requirements– less than 3 minutes in length– either be in English or French– can not contain violence, profanity, sex or direct attacks on individuals or organizations– must be your own original creation – no copyrighted music, video, or images may be usedSelectionAfter the competition closes on 1 March 2011, a shortlist of 20 finalists will be chosen by an OECD jury. These finalists will be announced in April and notified by e-mail, and the shortlisted videos will be showcased on the competition website.Subsequently, three winning videos will be selected by public voting on the OECD video competition on the Youtube Channel. The winners will be announced on 5 April 2011 and notified by e-mail, as well as published on the competition website.AwardThe video author (or nominated representative, if a team creation) of each winning video will be invited to Paris to attend the OECD 50th Anniversary Forum in May 2011. Travel costs to and from Paris, hotel accommodation and a living allowance will be provided for the duration of the [email protected] Webpagecenter_img OECD 50th Anniversary Video Competition Similar Stories European Blind Union full time Project Coordinator. Reddit +1 Tweet Active Participation at Local Level: Mobility and Activation of Youth, Greece →last_img read more

Insomniac Games hires Telltale lead writer

first_imgInsomniac Games hires Telltale lead writerThe Walking Dead: The Final Season scribe Mary Kenney starts at the Spider-Man studio in 2019James BatchelorEditor-in-ChiefTuesday 18th December 2018Share this article Recommend Tweet ShareCompanies in this articleInsomniac GamesTelltale GamesAnother key employee from Telltale Games has managed to secure a new role, this time at Insomniac Games.Mary Kenney announced via Twitter that she will be joining Insomniac in the New Year. She did not give details on what she would be working on, but given that the final DLC for Marvel’s Spider-Man released this month, it’s likely to be a new project.Kenney was only at Telltale Games for 16 months, but rose to lead writer on episode two of The Walking Dead: The Final Season after contributing to the Batman: The Enemy Within series.Acclaimed developer Telltale Games has collapsed over the past few months, starting with major layoffs of around 270 staff back in September. Since then, it has been revealed the studio is undergoing liquidation.The company was still working on The Walking Dead: The Final Season, although this has since been picked up by Skybound Games — the video games arm of the entertainment firm started by the IP’s creator Robert Kirkman.Skybound has said that “many” of the original team members from Telltale have been brought on board to finish the project — although it appears lead writer Kenney is not one of them.Kenney’s appointment highlights that there are still ex-Telltale staff seeking new roles after the sudden devastation of their former employer – something emphasised by narrative designer Emily Grace Buck a few weeks ago.Various industry members are still doing what they can to spread word of job opportunities via the Twitter hashtag #TelltaleJobs. Related JobsSenior Game Designer – UE4 – AAA United Kingdom Amiqus GamesProgrammer – REMOTE – work with industry veterans! North West Amiqus GamesJunior Video Editor – GLOBAL publisher United Kingdom Amiqus GamesDiscover more jobs in games Buck offered an in-depth post-mortem on what happened at the studio at this year’s Sweden Game Conference in October.[CORRECTION]: This article originally credited Kenney as lead writer on The Walking Dead: The Final Season. She only served as lead writer for the second episode of the season.If you have jobs news to share or a new hire you want to shout about, please contact us on [email protected] employer excellence in the video games industry8th July 2021Submit your company Sign up for The Daily Update and get the best of in your inbox. Enter your email addressMore storiesInsomniac re-casts Peter Parker’s face model in Spider-Man RemasteredBen Jordan to replace John Bubniak due to closer resemblance with voice actor Yuri LowenthalBy Rebekah Valentine 7 months agoSpider-Man Remastered won’t get physical PS5 releasePS4 save files from Marvel’s Spider-Man also won’t carry over to the PS5 versionBy Marie Dealessandri 7 months agoLatest comments Sign in to contributeEmail addressPasswordSign in Need an account? Register now.last_img read more